Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202004 | 0.82 | NQO1 (0.48) | CYP1A2CYP2C9LMNAMAPTRAB9A | |
| SCHEMBL6615348 | 0.81 | CYP1A2 (0.48) | CYP1A2CYP2C9HTTLMNAPTGS1 | |
| SCHEMBL21863285 | 0.81 | NOTUM (0.51) | CYP1A2HTTLMNAADORA3CA1 | |
| SCHEMBL13183810 | 0.80 | ALDH1A1 (0.45) | HTTLMNAADORA3MAPTMAPK10 | |
| SCHEMBL6132524 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2C9HTTLMNAPTGS2 | |
| SCHEMBL22897465 | 0.80 | CYP1A2 (0.47) | CYP1A2CYP2C9HTTLMNAPTGS1 | |
| SCHEMBL16202008 | 0.80 | RXRA (0.45) | HTTLMNAMAPTMAPK10KMT2A | |
| SCHEMBL14617482 | 0.80 | POLB (0.46) | PTGS2MAPTMAPK10POLBSMN1; SMN2 | |
| SCHEMBL6614645 | 0.77 | CYP1A2 (0.44) | CYP1A2CYP2C9HTTLMNAADORA3 | |
| SCHEMBL14617483 | 0.77 | RXRA (0.38) | CYP1A2CYP2C9LMNAPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10391076-B2 | Anti-cancer agent comprising aminoacetonitrile compound as active ingredient | PITNEY PHARMACEUTICALS PTY LTD. (AU) | 2019-08-27 | — | — | US | disclosed |
| US-10292960-B2 | Anticancer agent comprising aminoacetonitrile compound as active ingredient | PITNEY PHARMACEUTICALS PTY LIMITED (AU) | 2019-05-21 | — | — | US | disclosed |
| CN-106543092-B | Bis- aromatic radical -1,2,4- triazole compound of 1,5- and its pharmaceutical applications | 华东师范大学 | 2019-05-17 | — | — | CN | disclosed |
| US-20180207124-A1 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | PITNEY PHARMACEUTICALS PTY LIMITED (AU) | 2018-07-26 | — | — | US | disclosed |
| US-20180207124-A1 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | PITNEY PHARMACEUTICALS PTY LIMITED (AU) | 2018-07-26 | — | — | US | disclosed |
| US-9907778-B2 | Anticancer agent comprising aminoacetonitrile compound as active ingredient | PITNEY PHARMACEUTICALS PTY LIMITED (AU) | 2018-03-06 | — | — | US | disclosed |
| US-9907778-B2 | Anticancer agent comprising aminoacetonitrile compound as active ingredient | PITNEY PHARMACEUTICALS PTY LIMITED (AU) | 2018-03-06 | — | — | US | disclosed |
| US-20160249615-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2016-09-01 | — | — | US | disclosed |
| WO-2016137010-A1 | ANTI CANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | NIHON NOHYAKU CO., LTD. (JP) | 2016-09-01 | — | — | WO | disclosed |
| US-20160213640-A1 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | NIHON NOHYAKU CO., LTD. (JP) | 2016-07-28 | — | — | US | disclosed |
| US-20160145219-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | BASF SE (DE) | 2016-05-26 | — | — | US | disclosed |
| US-20160122327-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2016-05-05 | — | — | US | disclosed |
| US-9271501-B2 | Use of strobilurin type compounds for combating phytopathogenic fungi resistant to QO inhibitors | BASF SE (DE) | 2016-03-01 | — | — | US | disclosed |
| WO-2015037747-A1 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | NIHON NOHYAKU CO., LTD. (JP) | 2015-03-19 | — | — | WO | disclosed |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | BASF SE (DE) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122327-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | SNX1, DPM1, SNU13 | CYP1A2 2785/4885CYP2C9 4076/4885HTT 3148/4885 |
| US-10391076-B2 | Anti-cancer agent comprising aminoacetonitrile compound as active ingredient | RB1, CCNA1, CCNT1 | CYP1A2 2057/4885CYP2C9 2599/4885HTT 3003/4885 |
| US-20160145219-A1 | STROBILURIN TYPE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | DPM1, CROCC, SNX1 | CYP1A2 4047/4885CYP2C9 4742/4885HTT 2598/4885 |
| US-20160145202-A1 | Strobilurin Type Compounds for Combating Phytopathogenic Fungi | DPM1, CROCC, SNX1 | CYP1A2 4047/4885CYP2C9 4742/4885HTT 2598/4885 |
| US-20140323305-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | CYP1A2 335/4885CYP2C9 432/4885HTT 2375/4885 |
| US-10292960-B2 | Anticancer agent comprising aminoacetonitrile compound as active ingredient | RB1, CCNA1, NAT1 | CYP1A2 1324/4885CYP2C9 1843/4885HTT 2363/4885 |
| US-20160213640-A1 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | RB1, CCNA1, NAT1 | CYP1A2 1324/4885CYP2C9 1843/4885HTT 2363/4885 |
| US-20160249615-A1 | Use of Strobilurin Type Compounds for Combating Phytopathogenic Fungi Resistant to QO Inhibitors | SQOR, COX5B, UQCRB | CYP1A2 335/4885CYP2C9 432/4885HTT 2375/4885 |
| US-20180207124-A1 | ANTICANCER AGENT COMPRISING AMINOACETONITRILE COMPOUND AS ACTIVE INGREDIENT | RB1, CCNA1, NAT1 | CYP1A2 1324/4885CYP2C9 1843/4885HTT 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.